Profile data is unavailable for this security.
About the company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
- Revenue in USD (TTM)50.50bn
- Net income in USD4.91bn
- Incorporated1994
- Employees87.99k
- LocationSanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Mirati Therapeutics Inc | -12.85% | -- |
| Quten Research Institute LLC-Qunol | -8.30% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moderna Inc | 5.15bn | -5.97bn | 62.86bn | 5.60k | -- | 4.90 | -- | 12.20 | -15.66 | -15.66 | 13.51 | 33.46 | 0.2523 | 7.78 | 8.24 | 920,178.60 | -29.22 | 20.95 | -34.13 | 29.51 | 22.43 | -- | -115.82 | 32.10 | 3.91 | -- | 0.0429 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Zoetis Inc | 8.73bn | 2.39bn | 77.98bn | 14.10k | 32.94 | 15.44 | 27.03 | 8.93 | 5.19 | 5.19 | 18.95 | 11.07 | 0.6216 | 1.00 | 7.05 | 619,432.60 | 17.00 | 14.47 | 19.66 | 17.18 | 70.13 | 69.80 | 27.34 | 25.77 | 1.94 | 16.82 | 0.5659 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Gilead Sciences, Inc. | 27.45bn | 484.00m | 82.44bn | 18.00k | 184.02 | 4.70 | 25.75 | 3.00 | 0.3596 | 0.3596 | 21.89 | 14.08 | 0.4646 | 3.88 | 6.22 | 1,525,000.00 | 0.7718 | 6.74 | 0.9624 | 8.12 | 75.78 | 78.64 | 1.66 | 16.95 | 0.9365 | 13.67 | 0.5907 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Bristol-Myers Squibb Co | 45.53bn | -6.15bn | 84.21bn | 34.10k | -- | 5.11 | 22.59 | 1.85 | -3.10 | -3.10 | 22.15 | 8.14 | 0.4711 | 3.92 | 5.18 | 1,335,308.00 | -6.35 | 3.05 | -8.27 | 3.76 | 75.94 | 76.13 | -13.47 | 7.69 | 0.9947 | 15.57 | 0.7709 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Regeneron Pharmaceuticals Inc | 13.10bn | 3.86bn | 108.04bn | 13.45k | 28.96 | 4.00 | 25.17 | 8.25 | 33.86 | 33.86 | 114.89 | 244.93 | 0.4067 | 0.6974 | 2.53 | 973,985.10 | 11.98 | 20.18 | 13.36 | 23.22 | 86.32 | 86.63 | 29.45 | 38.11 | 4.51 | -- | 0.091 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
| Vertex Pharmaceuticals Incorporated | 10.19bn | 4.02bn | 116.33bn | 5.40k | 29.24 | 6.28 | 27.60 | 11.42 | 15.42 | 15.42 | 39.06 | 71.80 | 0.4749 | 1.98 | 6.10 | 1,886,111.00 | 18.74 | 19.92 | 22.29 | 23.64 | 86.86 | 87.67 | 39.46 | 35.85 | 3.29 | -- | 0.0191 | 0.00 | 10.51 | 26.49 | 8.96 | 46.50 | 22.02 | -- |
| Sanofi SA (ADR) | 50.50bn | 4.91bn | 123.55bn | 87.99k | 25.10 | -- | 16.36 | 2.45 | 1.95 | 1.95 | 20.14 | -- | -- | -- | -- | 573,854.80 | -- | 5.87 | -- | 7.16 | 68.74 | 68.78 | 10.14 | 16.90 | -- | 45.17 | -- | -- | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | -- |
| Pfizer Inc | 55.09bn | -288.00m | 162.57bn | 88.00k | -- | 1.76 | 25.87 | 2.95 | -0.0608 | -0.0645 | 9.71 | 16.28 | 0.2644 | 1.59 | 4.73 | 626,056.80 | -0.1219 | 8.20 | -0.1498 | 10.40 | 70.45 | 69.34 | -0.461 | 22.68 | 0.7784 | -- | 0.429 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 29.53bn | 3.76bn | 164.42bn | 26.70k | 43.80 | 32.74 | 19.73 | 5.57 | 7.00 | 7.00 | 54.97 | 9.36 | 0.3251 | 1.45 | 4.72 | 1,106,067.00 | 4.14 | 10.36 | 5.09 | 13.06 | 66.38 | 75.41 | 12.74 | 26.51 | 0.9793 | 2.46 | 0.9273 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Mar 2024 | 78.13m | 3.09% |
| Fisher Asset Management LLCas of 31 Mar 2024 | 13.95m | 0.55% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2024 | 13.07m | 0.52% |
| Managed Account Advisors LLCas of 31 Mar 2024 | 8.07m | 0.32% |
| Strategic Advisers LLCas of 31 Mar 2024 | 7.65m | 0.30% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 6.63m | 0.26% |
| Invesco Advisers, Inc.as of 31 Mar 2024 | 6.13m | 0.24% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 5.49m | 0.22% |
| Newton Investment Management North America LLCas of 31 Mar 2024 | 4.84m | 0.19% |
| Mondrian Investment Partners Ltd.as of 31 Mar 2024 | 3.95m | 0.16% |
